<DOC>
	<DOCNO>NCT02040558</DOCNO>
	<brief_summary>This multicenter , open-label , dose escalation study MNK-010 subject advance solid malignancy fail conventional therapy . The safety , tolerability , pharmacokinetic ( PK ) profile , preliminary antitumor activity ascend dos MNK-010 evaluate subject advance solid tumor .</brief_summary>
	<brief_title>Trial Study Safety Intravenous MNK-010 Advanced Solid Tumors</brief_title>
	<detailed_description />
	<criteria>Inclusion criterion : 1 . Diagnosis advance solid tumor malignancy . 2 . Histological cytological evidence malignancy . 3 . Advanced malignancy , metastatic unresectable , recur progress follow standard therapy fail standard therapy ; standard therapy currently exist , subject candidate , unwilling undergo , standard therapy . 4 . Disease currently amenable curative surgical intervention . 5 . Eastern Cooperative Oncology Group ( ECOG ) performance status 01 life expectancy &gt; 12 week . 6 . Subject ( and/or parent/guardian subject otherwise unable provide independent consent , acceptable approve site and/or site 's IRB ) must willing give write informed consent able adhere dose visit schedule . 7 . 18 year old , either sex , race 8 . Female subject childbearing potential must negative pregnancy test within 7 day prior first dose study drug ; practice acceptable form birth control great 2 month prior screen commits use duration study 3 month follow last dose study treatment . 9 . Male subject must sterile ( biologically surgically ) commit use reliable method birth control duration study least 3 month last dose study treatment manner risk pregnancy partner minimize . 10 . Prior study treatment administration , least 21 day must elapse since subject 's prior investigational noninvestigational systemic therapy , major surgery , least 21 day since prior radiotherapy . 11 . Subjects history prior radiotherapy eligible meet follow parameter : Prior study treatment administration , must ≥ 21 day posttherapy recovered toxicity ; must evidence measurable disease outside radiation field radiologically confirm progression disease ; must &gt; 25 % functional bone marrow irradiate . Must radiologically measureable disease , life expectancy &gt; 12 week , adequate organ function . 1 . Subject receive chemotherapy , immunotherapy , vaccine , monoclonal antibody , whether conventional investigational , major surgery within 21 day , radiotherapy within 21 day treatment study , time study . 2 . Subject active , uncontrolled systemic infection consider opportunistic , lifethreatening , clinically significant time treatment . 3 . Subject symptomatic untreated central nervous system ( CNS ) metastases ; type active seizure disorder ; febrile neutropenia ; ≥ Grade 2 peripheral neuropathy ; peritoneal pleural effusion require tap frequently every 14 day ; QT interval correct ( QTc ) prolongation prior history serious arrhythmia significant abnormality screen ECG ; previously experience severe reaction liposomal product taxane ; receive IV treatment bacterial/fungal infection within 7 day screen . 4 . Subject know significant cardiovascular disease cerebrovascular accident within 3 month enrollment , within timeframe stipulate additional criterion outline protocol . 5 . Subject require use follow concomitant treatments/procedures time , per protocol . 6 . Subject require either moderate strong ( weak , 2 ) inhibitor inducers Cytochrome P450 3A ( CYP3A ) mediate metabolism .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>